Mirati

MIRATI THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX

Retrieved on: 
Monday, October 9, 2023
Legal, Professional Services, NYSE, KSF, NSCLC, U.S. FDA, Patient, Bristol Myers Squibb, BMY, Contingent value rights, Sale, Pharmaceutical industry, Mirati

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Key Points: 
  • Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Mirati Therapeutics, Inc. (NasdaqGS: MRTX) to Bristol-Myers Squibb Company (NYSE: BMY).
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics

Retrieved on: 
Sunday, October 8, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Slate, Cancer, NYSE, Bristol Myers Squibb, Acquisition, Food, Cetuximab, KRAS, U.S. FDA, Cholangiocarcinoma, Central nervous system, Therapy, PRMT5, Accretion/dilution analysis, Disease, Morgan Stanley, FDA, VWAP, Doctor of Philosophy, Melanoma, Food and Drug Administration, MTAP, Kirkland & Ellis, CVR, Colorectal cancer, Chairperson, Science, Skadden, Arps, Slate, Meagher & Flom, News, Pancreatic cancer, MTA, Mirati Therapeutics, SOS1, MAPK, Centerview Partners, CNS, Life, BMY, Contingent value rights, PD-1, Patient, Financial toxicity, Pharmaceutical industry, Bank, NSCLC, Mirati

The transaction was unanimously approved by both the Bristol Myers Squibb and the Mirati Boards of Directors.

Key Points: 
  • The transaction was unanimously approved by both the Bristol Myers Squibb and the Mirati Boards of Directors.
  • Mirati’s assets are a strong fit with Bristol Myers Squibb’s portfolio and innovative pipeline and represent an attractive opportunity to grow Bristol Myers Squibb’s oncology franchise.
  • Through this acquisition, Bristol Myers Squibb will add KRAZATI, an important lung cancer medicine, to its commercial portfolio.
  • Bristol Myers Squibb expects to finance the acquisition with a combination of cash and debt.

MRTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mirati Therapeutics, Inc. Is Fair to Shareholders

Retrieved on: 
Monday, October 9, 2023
Legal, Professional Services, U.S. FDA, Sale, Bristol Myers Squibb, Fraud, Contingent value rights, NSCLC, Patient, Advertising, Security (finance), Mirati

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mirati Therapeutics, Inc. (NASDAQ: MRTX) to Bristol Myers Squibb for $58.00 per share in cash is fair to Mirati shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mirati Therapeutics, Inc. (NASDAQ: MRTX) to Bristol Myers Squibb for $58.00 per share in cash is fair to Mirati shareholders.
  • On behalf of Mirati shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
  • Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Mirati To Present Updated Clinical Data at ESMO Congress 2023

Retrieved on: 
Wednesday, September 27, 2023
KRAS, MB, ESMO, FRCPE, Mirati Therapeutics, Oncology, NSCLC, PST, NHS Grampian, Lung cancer, Harvard Medical School, Patient, Mass, SAN, CEST, Mirati, Hospital, NHS, European Society for Medical Oncology, Pembrolizumab, Therapy, GI, Treatment, Safety, Pharmaceutical industry, Music, Royal College of Pathologists

SAN DIEGO, Sept. 27, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage research and development biotechnology company, today announced several presentations to be unveiled at the European Society of Medical Oncology Congress 2023 taking place October 20 to 24, 2023 in Madrid, Spain, including updated clinical data showcasing the feasibility and potential of the investigational combination of KRASG12C inhibitor, adagrasib with pembrolizumab in a study of treatment naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.

Key Points: 
  • "Adagrasib is the first targeted KRASG12C inhibitor to show promising efficacy and early signs of durability in combination with an immune checkpoint inhibitor in the front line setting," said Alan Sandler , M.D.
  • chief medical officer, Mirati Therapeutics.
  • of Mass General Cancer Center, Harvard Medical School and Keith Kerr, MB ChB, FRCPath, FRCPE of NHS Grampian.
  • The symposium will be held on October 23 from 13:00-14:30 CEST in the Valencia Auditorium, Hall 10, IFEMA Madrid.

Pancreatic Cancer Battle Boosted by $200M VC Firm

Retrieved on: 
Tuesday, September 19, 2023
MACK, Rockefeller University, Stanford University, Pancreatic Cancer Action Network, MBA, Congress, Emerson Collective, MD, Patient, BNTX, Fast track (FDA), News, The New York Times, Interview, Ipsen, BioNTech, Mirati Therapeutics, Incyte, ONC, JD, Memorial Sloan Kettering Cancer Center, TSX, Metastasis, FDA, Roche, Pancreatic cancer, Oncolytics Biotech, Cancer, Lung cancer, MIT, Messenger, Mirati, MSK, Partnership, Pelareorep, Irinotecan, Merrimack Pharmaceuticals, American Cancer Society, FTD, Pharmaceutical industry, Genentech, Apple, Yosemite National Park, Research

VANCOUVER, BC, Sept. 19, 2023 /PRNewswire/ -- USA News Group  -  A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent individuals and institutions such as MIT,  Memorial Sloan Kettering Cancer Center and The Rockefeller University. Led by 31-year old Reed Jobs, the new firm dubbed 'Yosemite' appears to be an extension of the legacy left by the founder's father, Steve Jobs, the co-founder of Apple, who died in 2011 from a rare form of pancreatic cancer at the age of only 56. From an investment standpoint, the Global Pancreatic Cancer Market is expected to surpass US$7.4 billion by 2032, growing at a health CAGR of 13.7% along the way. Among the biotech sector's most promising developers of treatments for pancreatic cancer are Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Incyte Corporation (NASDAQ:INCY), Mirati Therapeutics, Inc. (NASDAQ:MRTX), and BioNTech SE (NASDAQ:BNTX).

Key Points: 
  • According to the American Cancer Society in its Cancer Facts & Figures 2023 report, the five-year survival rate for pancreatic cancer increased by 1% from the previous year to 12%.
  • In terms of targeting pancreatic cancer, the efforts align with the Pancreatic Cancer Action Network (PanCAN), which has been urging advocates from all 50 US states to call on Congress to increase federal funding for pancreatic cancer research.
  • These tests will be for people who have certain kinds of lung cancer, bowel cancer, pancreatic cancer, and other solid tumors, with Mirati providing Incyte with a drug called Adagrasib to use in the study.
  • The tailored neoantigen pancreatic cancer vaccine from BioNTech invoked an immune response in 50% of patients and prevented relapse.

Pancreatic Cancer Battle Boosted by $200M VC Firm

Retrieved on: 
Tuesday, September 19, 2023
MACK, Rockefeller University, Stanford University, Pancreatic Cancer Action Network, MBA, Congress, Emerson Collective, MD, Patient, BNTX, Fast track (FDA), News, The New York Times, Interview, Ipsen, BioNTech, Mirati Therapeutics, Incyte, ONC, JD, Memorial Sloan Kettering Cancer Center, TSX, Metastasis, FDA, Roche, Pancreatic cancer, Oncolytics Biotech, Cancer, Lung cancer, MIT, Messenger, Mirati, MSK, Partnership, Pelareorep, Irinotecan, Merrimack Pharmaceuticals, American Cancer Society, FTD, Pharmaceutical industry, Genentech, Apple, Yosemite National Park, Research

VANCOUVER, BC, Sept. 19, 2023 /PRNewswire/ -- USA News Group  -  A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent individuals and institutions such as MIT,  Memorial Sloan Kettering Cancer Center and The Rockefeller University. Led by 31-year old Reed Jobs, the new firm dubbed 'Yosemite' appears to be an extension of the legacy left by the founder's father, Steve Jobs, the co-founder of Apple, who died in 2011 from a rare form of pancreatic cancer at the age of only 56. From an investment standpoint, the Global Pancreatic Cancer Market is expected to surpass US$7.4 billion by 2032, growing at a health CAGR of 13.7% along the way. Among the biotech sector's most promising developers of treatments for pancreatic cancer are Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Incyte Corporation (NASDAQ:INCY), Mirati Therapeutics, Inc. (NASDAQ:MRTX), and BioNTech SE (NASDAQ:BNTX).

Key Points: 
  • According to the American Cancer Society in its Cancer Facts & Figures 2023 report, the five-year survival rate for pancreatic cancer increased by 1% from the previous year to 12%.
  • In terms of targeting pancreatic cancer, the efforts align with the Pancreatic Cancer Action Network (PanCAN), which has been urging advocates from all 50 US states to call on Congress to increase federal funding for pancreatic cancer research.
  • These tests will be for people who have certain kinds of lung cancer, bowel cancer, pancreatic cancer, and other solid tumors, with Mirati providing Incyte with a drug called Adagrasib to use in the study.
  • The tailored neoantigen pancreatic cancer vaccine from BioNTech invoked an immune response in 50% of patients and prevented relapse.

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, September 5, 2023
Employment, Therapy, RSU, Mirati Therapeutics, SAN, Pharmaceutical industry, Life insurance, Mirati

SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the company granted equity awards to 3 new employees with a grant date of September 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employee's acceptance of employment with the company.

Key Points: 
  • SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the company granted equity awards to 3 new employees with a grant date of September 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employee's acceptance of employment with the company.
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received, in the aggregate, options to purchase 25,531 shares of Mirati's common stock, and in the aggregate, 15,089 restricted stock units ("RSUs").
  • The options have an exercise price of $37.75 per share, which is equal to the closing price of Mirati's common stock on September 1, 2023, (the "Grant Date").

Mirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference

Retrieved on: 
Tuesday, August 29, 2023
Mirati, Webcast, Morgan, Therapy, Mirati Therapeutics, Conference, SAN, Pharmaceutical industry, Broadcasting

SAN DIEGO, Aug. 29, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Morgan Stanley 21st Annual Global Healthcare Conference on September 12 at 12:35 p.m. P.T.

Key Points: 
  • SAN DIEGO, Aug. 29, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Morgan Stanley 21st Annual Global Healthcare Conference on September 12 at 12:35 p.m. P.T.
  • Ben Hickey , chief commercial officer, and Jamie Christensen , Ph.D., chief scientific officer, will represent the company in a fireside chat at the conference.
  • Investors and the general public are invited to listen to a live webcast of the session through the "Investors and Media" section on Mirati.com .
  • A replay of the webcast will be made available following the event.

Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics

Retrieved on: 
Monday, August 28, 2023
Central Florida, KRAS, University, General counsel, Employment, Drug development, Senior, Blank Rome, Public policy, Mirati Therapeutics, Statistics, Clinical trial, Elicio Berriz, Cancer, TAP, Research, NSCLC, Boston University, History, Strategic planning, Patient, Rutgers School of Dental Medicine, Corporation, Corporate lawyer, Rutgers Journal of Law & Public Policy, FDA, Therapy, Rutgers Law School, Pharmaceutical industry, Wat Bang Khun Thian Nok, Biogen, Biometrics, Mirati, Law

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics.

Key Points: 
  • BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics.
  • She joined Molecular Templates as Corporate Counsel and during her time there, held roles of increasing responsibility, becoming General Counsel in February 2022.
  • Thian Kheoh, Ph.D., has over 30 years of drug development and clinical trial experience in the biopharmaceutical industry.
  • He most recently served as Vice President of Biometrics at Mirati Therapeutics where he led the Biometrics team in obtaining the FDA approval of KRAZATI® for KRAS G12C NSCLC patients.

Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer

Retrieved on: 
Wednesday, August 23, 2023
Arena Pharmaceuticals, CFO, Regeneron Pharmaceuticals, Therapy, Mirati Therapeutics, Financial management, Patient, FP, SAN, Strategic planning, Pharmaceutical industry, Management, Mirati

SAN DIEGO, Aug. 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that Laurie Stelzer, Chief Financial Officer, will depart the company on September 8, 2023, to pursue an external opportunity.

Key Points: 
  • SAN DIEGO, Aug. 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that Laurie Stelzer, Chief Financial Officer, will depart the company on September 8, 2023, to pursue an external opportunity.
  • Aaron Ondrey, senior vice president, financial planning and analysis (FP&A), Mirati Therapeutics, will assume the role of interim CFO.
  • "On behalf of the Board and the Company, we thank Laurie for her leadership and the contributions made during her tenure," said Charles M. Baum, M.D., Ph.D., interim CEO, president and founder, Mirati Therapeutics.
  • "It has been a privilege to serve as CFO of Mirati and I am grateful for the opportunity and the experience to work alongside a team committed to positively impacting the lives of patients," said Laurie Stelzer, chief financial officer, Mirati Therapeutics.